These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25724312)

  • 81. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization.
    Xu Y; Liu X; Lian R; Zheng S; Yin Z; Lu Y; Wu W
    Int J Pharm; 2012 Nov; 438(1-2):287-95. PubMed ID: 22989976
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Nanosuspensions: Enhancing drug bioavailability through nanonization.
    Chavhan R
    Ann Pharm Fr; 2024 Jun; ():. PubMed ID: 38945393
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Development and evaluation of intramuscularly administered nano/microcrystal suspension.
    Ma Z; Zhang H; Wang Y; Tang X
    Expert Opin Drug Deliv; 2019 Apr; 16(4):347-361. PubMed ID: 30827123
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
    Freag MS; Elnaggar YS; Abdallah OY
    Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
    Yang H; Teng F; Wang P; Tian B; Lin X; Hu X; Zhang L; Zhang K; Zhang Y; Tang X
    Int J Pharm; 2014 Dec; 477(1-2):88-95. PubMed ID: 25455766
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Honokiol nanosuspensions: preparation, increased oral bioavailability and dramatically enhanced biodistribution in the cardio-cerebro-vascular system.
    Han M; Yu X; Guo Y; Wang Y; Kuang H; Wang X
    Colloids Surf B Biointerfaces; 2014 Apr; 116():114-20. PubMed ID: 24448177
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.
    Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S
    Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263
    [TBL] [Abstract][Full Text] [Related]  

  • 89. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation.
    El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H
    Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Appraisal of Felodipine Nanocrystals for Solubility Enhancement and Pharmacodynamic Parameters on Cadmium Chloride Induced Hypertension in Rats.
    Maurya P; Pandey P; Singh S; Sonkar A; Singh S; Saraf SA
    Curr Drug Deliv; 2022; 19(5):625-634. PubMed ID: 34325637
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
    Merisko-Liversidge E; Liversidge GG
    Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Surface stabilized efavirenz nanoparticles for oral bioavailability enhancement.
    Jain S; Sharma JM; Agrawal AK; Mahajan RR
    J Biomed Nanotechnol; 2013 Nov; 9(11):1862-74. PubMed ID: 24059085
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
    Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam.
    Ambrus R; Kocbek P; Kristl J; Sibanc R; Rajkó R; Szabó-Révész P
    Int J Pharm; 2009 Nov; 381(2):153-9. PubMed ID: 19616609
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
    Kocbek P; Baumgartner S; Kristl J
    Int J Pharm; 2006 Apr; 312(1-2):179-86. PubMed ID: 16469459
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Efavirenz Loaded Mixed Polymeric Micelles: Formulation, Optimization, and
    Madan JR; Dere SG; Awasthi R; Dua K
    Assay Drug Dev Technol; 2021 Jul; 19(5):322-334. PubMed ID: 34129373
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Lipid based delivery of Efavirenz: An answer to its erratic absorption and food effect.
    Kamboj S; Sethi S; Rana V
    Eur J Pharm Sci; 2018 Oct; 123():199-216. PubMed ID: 30031861
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Recent survey on nanosuspension: a patent overview.
    Jethara SI; Patel AD; Patel MR; Patel MS; Patel KR
    Recent Pat Drug Deliv Formul; 2015; 9(1):65-78. PubMed ID: 25354346
    [TBL] [Abstract][Full Text] [Related]  

  • 99. D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension.
    Ghasemian E; Motaghian P; Vatanara A
    Adv Pharm Bull; 2016 Jun; 6(2):211-8. PubMed ID: 27478783
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Preparation and characterisation of nevirapine oral nanosuspensions.
    Raju A; Reddy AJ; Satheesh J; Jithan AV
    Indian J Pharm Sci; 2014 Jan; 76(1):62-71. PubMed ID: 24799740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.